The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
MDS 2023 | The need to incorporate disease-modifying drugs in lower-risk MDS
Maria Diez Campelo, MD, PhD, University of Salamanca, University Hospital Salamanca, discusses the need to incorporate disease-modifying drugs in the treatment of patients with lower-risk myelodysplastic syndromes (LR-MDS) to improve their outcomes. This interview took place at the 17th International Congress on Myelodysplastic Syndromes 2023 (MDS 2023) held in Marseille, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
